Narcolepsy Market expected to rise by 2032 | Companies- Axsome Therapeutics, Inc., Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, Alkermes, KemPharm, expected to drive market


The Narcolepsy market growth is driven by factors like increase in the prevalence of Narcolepsy, investments in research and development, entry of emerging therapies during the study period 2019-2032.


The Narcolepsy market report also offers comprehensive insights into the Narcolepsy market size, share, Narcolepsy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Narcolepsy market size growth forward. 


Some of the key highlights from the Narcolepsy Market Insights Report:


  • Several key pharmaceutical companies, including Axsome Therapeutics, Inc., Avadel Pharmaceuticals, Suven Life Sciences, Takeda, NLS Pharmaceutics, Vallon Pharmaceuticals, Alkermes, Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, XWPharma, Sunovion Pharmaceuticals, Otsuka Pharmaceutical, ConSynance Therapeutics, Alkermes, KemPharm, and others, are developing novel products to improve the Narcolepsy treatment outlook. 

  • Promising therapies in the Narcolepsy market are AXS-12, SUVN-G3031, TAK-994, Mazindol, ADAIR, Research Programme: Orexin 2 Receptor Agonist, ONO-2909, HBS 102, XW10172, Ulotaront, HBS 102, ALKS 2680, KP 1077, and others.

  • The total Narcolepsy market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.

  • As per DelveInsight analysis, the Narcolepsy market is anticipated to witness growth at a considerable CAGR


Strategise your business goals by understanding market dynamics @ Narcolepsy Market Landscape


Narcolepsy Overview 


Narcolepsy is a rare, chronic neurological disorder characterized by sudden, uncontrollable episodes of sleep. Individuals with narcolepsy experience excessive daytime sleepiness, struggling to stay awake and concentrate throughout the day. They may also have sleep attacks, where they unexpectedly fall asleep without warning. Another symptom is cataplexy, a temporary loss of muscle control that leads to weakness or even collapsing. Cataplexy is often triggered by strong emotions such as laughter or anger. Additionally, people with narcolepsy may have vivid dreams and wake up frequently during the night, with dreams occurring as they fall asleep or upon waking.


The underlying cause of narcolepsy is often a deficiency in hypocretin, a brain chemical that regulates alertness. Due to its rarity and many cases going undiagnosed, the exact prevalence of narcolepsy is difficult to determine. Currently, there is no cure for narcolepsy, but lifestyle changes to improve sleep habits and medication can help minimize the impact of the condition on daily life.


Do you know the treatment paradigms for different countries? Download our Narcolepsy Market Sample Report


Narcolepsy Epidemiology Segmentation 


DelveInsight’s Narcolepsy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Narcolepsy historical patient pools and forecasted Narcolepsy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Narcolepsy Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:


  • Narcolepsy Prevalence 

  • Age-Specific Narcolepsy Prevalence 

  • Gender-Specific Narcolepsy Prevalence 

  • Diagnosed and Treatable Cases of Narcolepsy


Visit for more @ Narcolepsy Epidemiological Insights


Recent Breakthroughs in the Narcolepsy Market:


  • In June 2023, RareStone Group, a rare disease-focused company aiming to establish China’s first rare disease ecosystem, announced that pitolisant (Wakix) was approved by the Chinese National Medical Products Administration (NMPA) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult narcolepsy patients.

  • In July 2023, the FDA evaluated the full protocol of NLS Pharmaceutics’ NLS-1031 research, which is part of the AMAZE program investigating Mazindol ER as a therapy for narcolepsy.



Narcolepsy Treatment Market 


The Narcolepsy market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Narcolepsy market trends by analyzing the impact of current Narcolepsy therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Narcolepsy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Narcolepsy market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Narcolepsy market in 7MM is expected to witness a major change in the study period 2019-2032.

Narcolepsy Therapy Assessment


AXS-12: Axsome therapeutics

AXS-12 (reboxetine) is a norepinephrine reuptake inhibitor that is being developed for the treatment of narcolepsy. It increases wakefulness, maintains muscle tone, and improves cognition by modulating noradrenergic activity. Reboxetine has a long track record of safety in Europe and over 40 countries where it is licensed for the treatment of depression. Positive pre-clinical and Phase 2 clinical data in patients with narcolepsy show that AXS-12 improves daytime drowsiness while decreasing cataplexy (sudden loss of muscle control) in an open-label pilot experiment. AXS-12 has been designated as an Orphan Drug by the US Food and Drug Administration (FDA) for the treatment of narcolepsy. The medication is now being examined in the Phase III development stage.

Narcolepsy Key Companies

  • Axsome Therapeutics

  • Avadel Pharmaceuticals

  • Suven Life Sciences

  • Takeda

  • NLS Pharmaceutics

  • Vallon Pharmaceuticals

  • Alkermes

  • Centessa Pharmaceuticals

  • Ono Pharma

  • Harmony Biosciences

  • Reset Therapeutics

  • XWPharma

  • Sunovion Pharmaceuticals

  • Otsuka Pharmaceutical

  • ConSynance Therapeutics

  • Alkermes

  • KemPharm

Narcolepsy Therapies

  • AXS-12

  • SUVN-G3031

  • TAK-994

  • Mazindol

  • ADAIR

  • Research Programme

  • Orexin 2 Receptor Agonist

  • ONO-2909

  • HBS 102

  • XW10172

  • Ulotaront

  • HBS 102

  • ALKS 2680

  • KP 1077

For more information, visit Narcolepsy Market Analysis, Patient Pool, and Emerging Therapies

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more